 SOUTH SAN FRANCISCO, Calif., July 09, 2021 GLOBE NEWSWIRE -- Tempest Therapeutics, Inc. Nasdaq: TPST, a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Sam Whiting, M.D., Ph.D., chief medical officer, will participate in a webcast panel titled Developing Therapies for the Next Immuno-Oncology Targets at the William Blair 2021 Biotech Focus Conference on Wednesday, July 14, 2021 at 2:10 p.m. ET. 